Trials / Conditions / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

13 registered clinical trials studyying High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in th NCT07069699	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363	University of Washington	Phase 2
Recruiting	Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment NCT05890352	SWOG Cancer Research Network	Phase 2
Recruiting	Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large NCT05600686	Joseph Tuscano	Phase 2
Suspended	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diag NCT04799275	National Cancer Institute (NCI)	Phase 2 / Phase 3
Unknown	Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphom NCT05097443	Shandong Provincial Hospital	Phase 3
Unknown	Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin NCT05164770	Shandong Provincial Hospital	Phase 3
Recruiting	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Agg NCT04231877	University of Washington	Phase 1
Active Not Recruiting	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Ly NCT04323956	Mayo Clinic	Phase 1
Completed	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large NCT03742258	Northwestern University	Phase 1
Active Not Recruiting	Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lympho NCT03749018	David Bond, MD	Phase 2
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2
Recruiting	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630	M.D. Anderson Cancer Center	Phase 1 / Phase 2